

Suite 500 902 Carnegie Center Princeton, NJ 08540-6531 +1 609 955 3200 Main +1 609 955 3259 Fax www.dechert.com

## **BRIAN GOLDBERG**

brian.goldberg@dechert.com +1 609 955 3205 Direct +1 609 955 3259 Fax

March 17, 2015

## VIA ECF

Honorable Thomas P. Griesa Daniel Patrick Moynihan United States Courthouse Southern District of New York Courtroom 26B 500 Pearl Street New York, NY 10007-1312

Re: Endo Pharms. Inc., et al. v. Actavis Inc., et al., No. 13-cv-0436;
Endo Pharms. Inc. v. Actavis Inc., et al., No. 12-cv-8985;
Endo Pharms. Inc., et al., v. Amneal Pharms., LLC, et al., No. 12-cv-8115;
Endo Pharms. Inc., et al., v. Impax Labs., Inc., No. 13-cv-0435;
Endo Pharms. Inc., et al., v. Impax Labs. Inc. et al., No. 12-cv-8317;
Endo Pharms. Inc. v. Par Pharm. Cos., Inc., et al., No. 13-cv-3284;
Endo Pharms. Inc., et al., v. Par Pharm. Cos., Inc., et al., No. 12-cv-9261;
Endo Pharms. Inc. v. Ranbaxy Labs. Ltd., et al., No. 13-cv-4343;
Endo Pharms. Inc. v. Roxane Labs., No. 13-cv-3288;
Endo Pharms. Inc., et al., v. Sandoz Inc., No. 12-cv-8318;
Endo Pharms. Inc., et al. v. Teva Pharms. USA, Inc., et al., No. 12-cv-8060

## Dear Judge Griesa:

Pursuant to Rule 1(A) of Your Honor's Individual Practices, we write with the consent of all parties to the above-referenced actions to request permission for Plaintiffs' witness, Dr. Chris Rauwendaal, to be allowed to complete his rebuttal testimony, potentially out of sequence, on April 2, 2015, in order to accommodate a previously scheduled overseas speaking engagement. We understand that the Court will not hold session on April 3. If that understanding is not correct, then Dr. Rauwendaal would have to complete his rebuttal testimony by April 3.



Honorable Thomas P. Griesa U.S.D.J. March 17, 2015 Page 2

The parties thank the Court for its consideration of this request.

Respectfully submitted,

Brian M. Goldberg

cc: All counsel of record (via ECF)